
Multiple Sclerosis Drugs Market
Multiple Sclerosis Drugs Market - Global Industry Assessment & Forecast
Segments Covered
By Drug Class Immunosuppressants, Immunomodulators, Interferons, Other Drug Classes
By Route of Administration Oral, Injectable
By Distribution Channel Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
![]() |
2024 |
![]() |
2025 - 2035 |
![]() |
2019 - 2023 |
![]() |
USD 23.2 Billion |
![]() |
USD 53.25 Billion |
![]() |
7.85% |
![]() |
Asia Pacific |
![]() |
North America |
Customization Offered
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market Dynamics
Region Level Market Share
Import Export Analysis
Production Analysis
Others Request Customization Speak To Analyst
-
Executive Dashboard
- Strategic Imperatives
-
Premium Insights
- Top 3 Trends to Watch
- Demand and Supply Trends
- Top 3 Strategies Followed by Major Players
- Top 3 Predictions by Vantage Market Research
- Top Investment Pockets
- Insights from Primary Respondents
-
Global Multiple Sclerosis Drugs Market - Segment Analysis
- Overview
- Global Multiple Sclerosis Drugs Market, 2016 - 2028 (USD Million)
-
Global Multiple Sclerosis Drugs Market - by Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
-
Global Multiple Sclerosis Drugs Market - by Route of Administration
- By Oral
- By Injectable
-
Global Multiple Sclerosis Drugs Market - by Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
-
Global Multiple Sclerosis Drugs Market - by region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Market comparative analysis
-
North America Multiple Sclerosis Drugs Market - Segment Analysis
- Overview
- North America Multiple Sclerosis Drugs Market, 2016 - 2028 (USD Million)
-
North America Multiple Sclerosis Drugs Market, by Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
-
North America Multiple Sclerosis Drugs Market, by Route of Administration
- By Oral
- By Injectable
-
North America Multiple Sclerosis Drugs Market, by Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
-
North America Multiple Sclerosis Drugs Market, by Country
- U.S.
- U.S. Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- U.S. Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- U.S. Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- U.S. Multiple Sclerosis Drugs Market, By Drug Class
- Canada
- Canada Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- Canada Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- Canada Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- Canada Multiple Sclerosis Drugs Market, By Drug Class
- Mexico
- Mexico Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- Mexico Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- Mexico Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- Mexico Multiple Sclerosis Drugs Market, By Drug Class
- U.S.
-
Europe Multiple Sclerosis Drugs Market - Segment Analysis
- Overview
- Europe Multiple Sclerosis Drugs Market, 2016 - 2028 (USD Million)
-
Europe Multiple Sclerosis Drugs Market, by Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
-
Europe Multiple Sclerosis Drugs Market, by Route of Administration
- By Oral
- By Injectable
-
Europe Multiple Sclerosis Drugs Market, by Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
-
Europe Multiple Sclerosis Drugs Market, by Country
- Germany
- Germany Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- Germany Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- Germany Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- Germany Multiple Sclerosis Drugs Market, By Drug Class
- UK
- UK Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- UK Market, By Route of Administration
- By Oral
- By Injectable
- UK Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- UK Market, By Drug Class
- France
- France Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- France Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- France Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- France Multiple Sclerosis Drugs Market, By Drug Class
- Spain
- Spain Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- Spain Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- Spain Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- Spain Multiple Sclerosis Drugs Market, By Drug Class
- Italy
- Italy Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- Italy Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- Italy Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- Italy Multiple Sclerosis Drugs Market, By Drug Class
- BENELUX
- BENELUX Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- BENELUX Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- BENELUX Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- BENELUX Multiple Sclerosis Drugs Market, By Drug Class
- Rest of Europe
- Rest Of Europe Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- Rest Of Europe Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- Rest Of Europe Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- Rest Of Europe Multiple Sclerosis Drugs Market, By Drug Class
- Germany
-
Asia Pacific Multiple Sclerosis Drugs Market - Segment Analysis
- Overview
- Asia Pacific Multiple Sclerosis Drugs Market, 2016 - 2028 (USD Million)
-
Asia Pacific Multiple Sclerosis Drugs Market, by Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
-
Asia Pacific Multiple Sclerosis Drugs Market, by Route of Administration
- By Oral
- By Injectable
-
Asia Pacific Multiple Sclerosis Drugs Market, by Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
-
Asia Pacific Multiple Sclerosis Drugs Market, by Country
- China
- China Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- China Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- China Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- China Multiple Sclerosis Drugs Market, By Drug Class
- Japan
- Japan Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- Japan Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- Japan Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- Japan Multiple Sclerosis Drugs Market, By Drug Class
- India
- India Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- India Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- India Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- India Multiple Sclerosis Drugs Market, By Drug Class
- South Korea
- South Korea Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- South Korea Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- South Korea Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- South Korea Multiple Sclerosis Drugs Market, By Drug Class
- South East Asia
- South East Asia Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- South East Asia Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- South East Asia Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- South East Asia Multiple Sclerosis Drugs Market, By Drug Class
- Rest of Asia Pacific
- Rest of Asia Pacific Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- Rest of Asia Pacific Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- Rest of Asia Pacific Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- Rest of Asia Pacific Multiple Sclerosis Drugs Market, By Drug Class
- China
-
Latin America Multiple Sclerosis Drugs Market - Segment Analysis
- Overview
- Latin America Multiple Sclerosis Drugs Market, 2016 - 2028 (USD Million)
-
Latin America Multiple Sclerosis Drugs Market, by Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
-
Latin America Multiple Sclerosis Drugs Market, by Route of Administration
- By Oral
- By Injectable
-
Latin America Multiple Sclerosis Drugs Market, by Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
-
Latin America Multiple Sclerosis Drugs Market, by Country
- Brazil
- Brazil Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- Brazil Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- Brazil Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- Brazil Multiple Sclerosis Drugs Market, By Drug Class
- Argentina
- Argentina Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- Argentina Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- Argentina Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- Argentina Multiple Sclerosis Drugs Market, By Drug Class
- Rest of Latin America
- Rest of Latin America Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- Rest of Latin America Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- Rest of Latin America Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- Rest of Latin America Multiple Sclerosis Drugs Market, By Drug Class
- Brazil
-
Middle East & Africa Multiple Sclerosis Drugs Market - Segment Analysis
- Overview
- Middle East & Africa Multiple Sclerosis Drugs Market, 2016 - 2028 (USD Million)
-
Middle East & Africa Multiple Sclerosis Drugs Market, by Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
-
Middle East & Africa Multiple Sclerosis Drugs Market, by Route of Administration
- By Oral
- By Injectable
-
Middle East & Africa Multiple Sclerosis Drugs Market, by Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
-
Middle East & Africa Multiple Sclerosis Drugs Market, by Country
- GCC Countries
- GCC Countries Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- GCC Countries Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- GCC Countries Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- GCC Countries Multiple Sclerosis Drugs Market, By Drug Class
- South Africa
- South Africa Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- South Africa Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- South Africa Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- South Africa Multiple Sclerosis Drugs Market, By Drug Class
- Rest of Middle East & Africa
- Rest of Middle East & Africa Multiple Sclerosis Drugs Market, By Drug Class
- By Immunosuppressants
- By Immunomodulators
- By Interferons
- By Other Drug Classes
- Rest of Middle East & Africa Multiple Sclerosis Drugs Market, By Route of Administration
- By Oral
- By Injectable
- Rest of Middle East & Africa Multiple Sclerosis Drugs Market, By Distribution Channel
- By Hospital Pharmacy
- By Retail Pharmacy
- By Online Pharmacy
- Rest of Middle East & Africa Multiple Sclerosis Drugs Market, By Drug Class
- GCC Countries
-
Key Market Dynamics
- Introduction
- Market Drivers
- Market Restraints
- Market Opportunities
- Porter's Five Forces Analysis
- PEST Analysis
- Regulatory Landscape
- Technology Landscape
- Regional Market Trends
-
COVID 19 Impact Analysis
- Key strategies undertaken by companies to tackle COVID-19
- Short term dynamics
- Long term dynamics
-
Marketing Stratagy Analysis
- Marketing Channel
- Direct Marketing
- Indirect Marketing
- Marketing Channel Development Trends
-
Competative Landscape
- Competition Matrix - 2021
- Company Market Share Analysis - 2021
- Key Company Activities, 2018 - 2021
- Strategic Developments - Heat Map Analysis
- Company Offering Evaluation
- Company Regional Presence Evaluation
-
Company Profiles
- Celgene Corporation
- Acorda Therapeutics Inc.
- Biogen Inc.
- Actelion Pharmaceuticals (Johnson & Johnson)
- EMD Serono (Merck KGaA)
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Novartis AG.
- Sanofi
- F. Hoffmann-La Roche Ltd.
- Key Primary Respondents - VERBATIM
- Discussion Guide
- Customization Offered
- Annexure
- List of Figures
- List of Tables
- List of Abbreviations
FAQ
Frequently Asked Question
What is the global demand for Multiple Sclerosis Drugs in terms of revenue?
-
The global Multiple Sclerosis Drugs valued at USD 23.2 Billion in 2024 and is expected to reach USD 53.25 Billion in 2035 growing at a CAGR of 7.85%.
Which are the prominent players in the market?
-
The prominent players in the market are Celgene Corporation, Acorda Therapeutics Inc., Biogen Inc., Actelion Pharmaceuticals (Johnson & Johnson), EMD Serono (Merck KGaA), Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG., Sanofi, F. Hoffmann-La Roche Ltd..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 7.85% between 2025 and 2035.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Multiple Sclerosis Drugs include
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Multiple Sclerosis Drugs in 2024.